Drug Trial Radar · NCT06344104
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Apr 8, 2024
Primary completion
Nov 24, 2025
Study completion Apr 3, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of baxdrostat in participants with uHTN or rHTN. The main objective is to compare the difference in SBP change from baseline at Week 12 of treatment between participants receiving 2 mg baxdrostat or 1 mg baxdrostat tablets and participants receiving placebo tablets.
Conditions
- Uncontrolled Hypertension
- Resistant Hypertension
Interventions
BaxdrostatDrug
Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: * 1 mg per tablet for 1mg baxdrostat Arm * 2 mg per tablet for 2mg baxdrostat Arm
PlaceboDrug
Placebo tablet administered orally, once daily (QD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in seated SBP at Week 12Time frame: At Week 12
Locations
93 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Bahía Blanca, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad de Buenos Aires, Argentina
Research Site
San Miguel de Tucumán, Argentina
Research Site
San Nicolás de los Arroyos, Argentina
Research Site
Coffs Harbour, Australia
Research Site
Gosford, Australia
Research Site
Hoppers Crossing, Australia
Research Site
Ipswich, Australia
Research Site
Baotou, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Bengbu, China
Research Site
Changde, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Changzhou, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Chongqing, China
Research Site
Chongqing, China
Research Site
Deyang, China
Research Site
Guangzhou, China
Research Site
Ha’erbin, China
Research Site
Hangzhou, China
Research Site
Hefei, China
Research Site
Heze, China
Research Site
Jiujiang, China
Research Site
Luoyang, China
Research Site
Meihekou, China
Research Site
Nanchang, China
Research Site
Nanchong, China
Research Site
Nanjing, China
Research Site
Panjin, China
Research Site
Sanya, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Shenyang, China
Research Site
Taiyuan, China
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.